Skip to main content

Table 2 Patient characteristics

From: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Characteristic

Patients

 

(N = 72)

Age, years

 

Median (SD)

58.0 (12.4)

Range

23–78

Gender, n (%)

 

Male

36 (50.0)

Female

36 (50.0)

ECOG PS, n (%)

 

0

22 (31)

1

49 (68)

Not recorded

1 (1)

Tumor type, n (%)

 

NSCLC

13 (18.0)

Breast

10 (13.8)

Melanoma

6 (8.3)

Pancreas

5 (6.9)

Prostate

4 (5.6)

Colon

4 (5.6)

Esophagus

3 (4.2)

Parotid

3 (4.2)

SCLC

3 (4.2)

Othera

21 (29.2)

  1. Abbreviations: SD standard deviation, ECOG Eastern Cooperative Oncology Group, PS performance status, SCLC small cell lung cancer, SCC squamous cell cancer.
  2. aCervical, cholangiocarcinoma, gastric, mesothelioma, endothelial cell, bladder, renal, sarcoma, SCC orbit, SCC vagina, SCC vulva, anal, tonsil, hard palate, and vulva.